GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2024, and provided a business update. Cash Position and Outlook GenSight Biologics' cash and cash equivalents totalled €3.4